Search - tctmd.com

Displaying 21 - 40 of 45

Sort: Relevancy | Date

Retracted Over Fraud Concerns, Surgisphere ACE/ARB Study Still Gets Cited

News Daily News

Retracted Over Fraud Concerns, Surgisphere ACE/ARB Study Still Gets Cited

Michael O'Riordan

August 03, 2021

Heart Failure Patients With AF Benefit From Early Rhythm Control

News Conference News HRS 2021

Heart Failure Patients With AF Benefit From Early Rhythm Control

July 30, 2021

Optimizing Medical Therapy Before Clip Repair for MR? ‘This is Hard’

News Conference News TVT 2021

Optimizing Medical Therapy Before Clip Repair for MR? ‘This Is Hard’

July 27, 2021

Studies Explore Post-MI Use of Beta-blockers, Mineralocorticoid Receptor Antagonists

News Daily News

Studies Explore Post-MI Use of Beta-blockers, Mineralocorticoid Receptor Antagonists

July 09, 2021

Beta-blocker Withdrawal Boosts Peak VO2 in HFpEF Subset: PRESERVE-HR

News Conference News ESC Heart Failure 2021

Beta-blocker Withdrawal Boosts Peak VO2 in HFpEF Subset: PRESERVE-HR

July 06, 2021

Empagliflozin Succeeds in HFpEF: EMPEROR-Preserved Top-line Results

News Daily News

Empagliflozin Succeeds in HFpEF: EMPEROR-Preserved Top-line Results

July 06, 2021

Less Cancer Among HF Patients Taking Statins, Registry Shows

News Daily News

Less Cancer Among HF Patients Taking Statins, Registry Shows

Michael O'Riordan

June 23, 2021

Stopping Statins Ups CVD and Mortality Risks in Pill-Burdened Seniors

News Daily News

Stopping Statins Ups CVD and Mortality Risks in Pill-Burdened Seniors

Michael O'Riordan

June 16, 2021

Moderate Aortic Stenosis and HFrEF Combo Portends Poor Survival, Study Finds

News Daily News

Moderate Aortic Stenosis and HFrEF Combo Portends Poor Survival, Study Finds

June 03, 2021

Dapagliflozin US Cost-effectiveness Data Expose Barriers to HF Care

News Daily News

Dapagliflozin US Cost-effectiveness Data Expose Barriers to HF Care

May 27, 2021

Sotagliflozin Beneficial Across a Range of Patients, Including HFpEF

News Conference News ACC 2021

Sotagliflozin Beneficial Across a Range of Patients, Including HFpEF

Michael O'Riordan

May 25, 2021

Omecamtiv Mecarbil Has Biggest Benefit at Lowest EFs

News Conference News ACC 2021

Omecamtiv Mecarbil Has Biggest Benefit at Lowest EFs

May 18, 2021

PARADISE-MI: ARNI Doesn’t Surpass ACE Inhibitor After Acute MI

News Conference News ACC 2021

PARADISE-MI: ARNI Doesn’t Surpass ACE Inhibitor After Acute MI

May 15, 2021

‘Enormous’ QoL Improvements With Mavacamten in HCM

News Conference News ACC 2021

‘Enormous’ QoL Improvements With Mavacamten in HCM

May 15, 2021

FDA Approves Dapagliflozin for CKD Patients

News Daily News

FDA Approves Dapagliflozin for CKD Patients

Michael O'Riordan

May 03, 2021

Belly Fat the Biggest Driver of Obesity-Related CVD, Says AHA

News Daily News

Belly Fat the Biggest Driver of Obesity-Related CVD, Says AHA

Michael O'Riordan

April 26, 2021

Hints of Benefit With Levosimendan in Pulmonary Hypertension Due to HFpEF

News Daily News

Hints of Benefit With Levosimendan in Pulmonary Hypertension Due to HFpEF

Michael O'Riordan

April 15, 2021

Continue ACE Inhibitors/ARBs in COVID-19, New Study Confirms

News Daily News

Continue ACE Inhibitors/ARBs in COVID-19, New Study Confirms

Michael O'Riordan

April 02, 2021

New FDA Indication Opens Up Use of Sacubitril/Valsartan in HFpEF

News Daily News

New FDA Indication Opens Up Use of Sacubitril/Valsartan in HFpEF

February 16, 2021

Did Regional Differences Muddy Results in COMMANDER-HF?

News Daily News

Did Regional Differences Muddy Results in COMMANDER-HF?

February 04, 2021

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.